Press Release

Aarti Drugs reported FY26 PAT up 16% to Rs 194.9 Cr, with revenue at Rs 2,567.7 Cr (+7%). Q4 saw strong sequential recovery: revenue Rs 721.1 Cr (+20% QoQ), EBITDA Rs 96.6 Cr (+72% QoQ), driven by Sayakha facility scale-up and better product mix.

Formulations and Specialty Chemicals showed strong segment growth.